Company Active LTD

Company profile

Evonetix Ltd

DNA synthesis technology to ignite the engineering biology revolution

Spearheading a radical new approach to gene synthesis to improve access to high-quality, gene-length DNA. Redefine possible.

CRN
09440594
Founded
2015
Age
11

Overview

Legal name
EVONETIX LTD
Region
East of England
Registered address
UNIT 1 CAMBRIDGE HOUSE CAMBORO BUSINESS PARK OAKINGTON ROAD
GIRTON
CAMBRIDGE
ENGLAND
CB3 0QH
Insolvency history
No

Corporate ownership

Updated 06 Jun 2026 16:52

Evonetix Ltd
No active corporate controller recorded.

Company events

Reference milestones and recent Companies House filing stream events.

8 events
31 Jul
2027

Accounts due

Accounts Due

Next accounts due date

17 May
2027

Confirmation statement due

Confirmation Due

Next confirmation statement due date

03 May
2026

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Oct
2025

Accounts filed

Accounts

Last accounts made up date

20 Feb
2025

Capital Allotment Shares

Capital

SH01 | Transaction MzQ1NTgwNzc1NmFkaXF6a2N4

Published 20 Feb 2025 10:46

21 Oct
2024

Termination Secretary Company With Name Termination Date

Officers

TM02 | Transaction MzQ0MDI4NTA1MGFkaXF6a2N4

Published 21 Oct 2024 10:43

18 Oct
2024

Change Account Reference Date Company Current Shortened

Accounts Awaiting analysis

AA01 | Transaction MzQ0MDA3NDk2OWFkaXF6a2N4

Published 18 Oct 2024 12:55

16 Feb
2015

Incorporated

Inception

Company registered at Companies House

Public funding

1 award
First funded
2018
Funded years
2018, 2020
Age at first award
3 years

Projects

2020 Feasibility Studies Lead participant

Enzymatic gene synthesis

1 Jun 2020 to 30 Nov 2020

Awarded
£75,750
Total cost £75,750

no public description

2018 Collaborative R&D Lead participant

Enzymatic gene synthesis

1 Jul 2018 to 30 Jun 2021

Awarded
£653,128
Total cost £933,040

"The revolution generated by next-generation sequencing platforms led to a massive increase in DNA sequence information becoming available over the past ten years. There now exists an unprecedented opportunity to engineer metabolic pathways and organisms, improve industrial processes, create new processes, engineer genomes with new and improved traits and...

Product types

Collaborative R&D Feasibility Studies